The Coronavirus Crisis: Challenges and Opportunities for CMOs, CDMOs and CROs
The coronavirus crisis caused by the Covid-19 pandemic has uncovered problems that have been smoldering beneath the surface of the pharmaceutical industry — including CMOs/CDMOs and CROs — and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
The ongoing pandemic is putting pharmaceutical R&D strategies to the test and also challenging manufacturing planning and supply chain management. Particularly in this industry segment, the supply chain is global, complex and interconnected. Each link must be strong enough to ensure that the road from lab to final drug product is as smooth as possible, even under the most difficult circumstances.
In addition to the pandemic, the growing threat of a no-deal-Brexit amid old and new trade conflicts and increasing protectionism, is putting even more stress on companies operating in the pharma sector.
In cooperation with Wombat Capital*, a cross-border investment bank, CHEManager asked executives and experts of CMOs, CDMOs and CROs operating in the pharmaceutical sector to share their opinion on current challenges for their industry and how these challenges may influence changes in their market and opportunities.
Read the insightful answers of the experts here.
-
Expert Interview: Michael Quirmbach, CordenPharma
-
Expert Interview: Peter Pekos, Dalton Pharma Services
-
Expert Interview: GianMarco Negrisoli, Flamma
-
Expert Interview: Jean-Luc Herbeaux, Hovione
-
Expert Interview: Andrew Thompson, J-Star
-
Expert Interview: David Zimmermann, Kalexsyn
-
Expert Interview: Alan Walker, Kaneka
-
Expert Interview: Matthew Moorcroft, Lonza
-
Expert Interview: Peter Halkjaer-Knudsen, Raybow Pharmaceuticals
-
Expert Interview: Mark Quick, Recipharm
-
Expert Interview: Andrew Henderson, Sterling Pharma Solutions
* Cross-border investment bank Wombat Capital provides mergers and acquisitions and strategic advisory services. With offices in New York and Paris, Wombat Capital focuses on the CDMO/CRO and pharma outsourcing sectors.
most read
Substances of Concern
The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.
Q1 2025 Chemical Industry: Diverging Trends
The first quarter of 2025 highlights a continued divergence between the European and US chemical industries.
“Access to Talent is a Crucial Factor”
In an interview with CHEManager, Edgardo Hernandez, President of Lilly Manufacturing, explains the strategy behind the ambitious investment project.
Pharma Outlook 2025
The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.
The Future of Demand for Chemicals
The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.